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Abstract
Piwi proteins have been implicated in germ cell proliferation, differentiation, germline stem cell maintenance and
transposon control in germline from Drosophila to mammals. The Piwi-like2 (piwil2) gene is mainly expressed in testis or
embryonic cells among normal tissues but widely expressed in tumors. However, it remains to be fully determined through
which mechanism piwil2 is involved in tumorigenesis. Here we report that Human piwil2, or Hili represses the tumor
suppressor P53 in human cancer cells. Immunoprecipitation analysis shows that Piwil2 can directly associate with Signal
Transducer and Activator of Transcription 3 (STAT3) protein via its PAZ domain and form a Piwil2/STAT3/c-Src triple protein-
protein complex. Furthermore, STAT3 is phosphorylated by c-Src and translocated to nucleus, then binds to P53 promoter
and represses its transcription. The present study demonstrated that Piwil2 plays a role in anti-apoptosis in tumor cells
possessing P53 as a positive regulator of STAT3 signaling pathway, providing novel sights into roles of Piwil2 in
tumorigenesis.
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Introduction
The Argonaute gene family which encode basic proteins that
contain both PAZ and Piwi conserved domains, have been
reported to induce histone and DNA methylation, mRNA
breakdown and inhibition of translation [1,2]. As a predominantly
germline specific clade of Argonaute gene family, Piwi subfamily
are found in all animals tested so far and play essential roles in
stem-cell self-renewal, gametogenesis and RNA silencing in diverse
organisms [3–8]. Mutations of three Piwi homologs in mice (miwi,
mili and miwi2) respectively cause arrestment of spermatogenesis
and male sterility [9–11].
The piwil2 gene, alias mili in mouse or Hili in human, is mainly
expressed in testis or embryonic cells among normal tissues but
widely expressed in tumors, suggesting that Piwil2 may disturb cell
division, inhibit apoptosis and play a role as dose-dependent
oncogenic fate determinants. However, the underlying mechanism
through which Piwil2 involved in tumorigenesis remains largely
unknown yet [12,13].
The tumor suppressor p53 which involved in a number of
cellular signaling pathways is known to play an essential role in
regulating apoptosis. Loss of P53 function is a common feature of
many human cancers [14–16]. Though deletions or mutations of
P53 have been observed in a great number of tumors, the HeLa
cell line possesses wild-type P53 alleles detectable in both mRNA
and protein level [17]. Interestingly, Lin et al. reported that in
prostate cancer cell lines wild-type but not mutant P53 can
significantly inhibit STAT3 activity, whereas it has also been
reported that STAT3 can bind to P53 promoter and inhibit the
P53 gene transcription rate [18,19].
STAT signaling pathways activated in response to cytokines and
growth factors have been reported to constitutively express in
varied tumor-derived cell lines and tumor tissues [20]. STAT3
activation can resist apoptotic machinery relied anti-tumor
therapies, and also enhance the growth of tumor cell [18].
Because its activation can mediate oncogenic transformation in
cultured cells and tumor formation in nude mice, Stat3 has been
classified as an oncogene [21]. Here we present that human piwil2
gene suppresses apoptosis by phosphorylating STAT3 along with
c-Src and initiating transcriptional silencing of P53.
Results
Piwil2 inhibits P53 involved apoptosis in HeLa Cells
Previous studies have reported that Piwil2 is expressed in
various tumors and inhibits apoptosis when transfected into
embryo fibroblast cells [13]. To investigate the role which human
piwil2 protein, alias HILI plays in tumorigenesis and apoptosis in
cancer cells, expression vectors and siRNAs were transfected into
HeLa Cells. Real-time qPCR and Western blot analysis revealed
that there was a significant decrease in P53 expression following
the over-expression of Piwil2 in both mRNA and protein level,
while its counterpart, Piwil2-knockdowned HeLa cells express a
higher level of P53 (Fig. 1A). We also examined several other
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showed that the level of P21 significantly increased when Piwil2
was knockdowned, while slightly decreased when Piwil2 was
overexpressed (Fig. 1B).
Fluorescence activated cell sorter (FACS) analysis showed a
significant decrease of apoptosis from 31.4% to 24.8%, while its
counterpart, piwil2-knockdowned HeLa cells increased to 48.4%.
Notably, when P53 specific siRNA was co-transfected into piwil2-
knockdowned HeLa cells, apoptosis ratio significantly decreased to
33.9% (Fig. 1C), suggesting that P53 is essential for apoptosis
pathway induced by Piwil2-knockdown.
However, immunoprecipitation assay revealed that Piwil2 can
not directly associate with P53 (Fig. 1D), suggesting the existence
of a potential pathway through which Piwil2 can regulate P53 and
inhibit apoptosis in tumor cells.
Piwil2 suppresses P53 signaling by phosphorylating
STAT3
Examination revealed that STAT3 knockdown can block
inhibition of P53 expression and apoptosis induced by Piwil2
overexpression (Fig. 1C), indicating that STAT3 protein may play
a role between piwil2 and P53 suppression. To determine the
underlying mechanism, a western blot analysis was performed to
detect the phosphorylation of STAT3, which represents the
activation of this transcription factor [22]. A significant increase
was observed in Piwil2-overexpressed HeLa Cells 12 hours after
transfection. However, after 24 hours, the level of pYSTAT3
resumed its normal level approximately. In contrast, pYSTAT3
level decreased and then recovered after 24 hours in Piwil2-
knockdown HeLa cells (Fig. 2A). Immunofluorescence assay also
revealed that pYSTAT3 signal increased in cytoplasm 6 hours
after pcDNA3.1-Piwil2 transfection (Fig. 2B).
To evaluate the time-course of STAT3 activity and P53
expression, HeLa cells harvested from various time points after
transfection was analyzed by western-blotting. The pYSTAT3
level had been boosted just 3 hours after transfection of
pcDNA3.1-Piwil2 and continuously increased until 9 hours,
whereas the level of P53 showed no more than a slight change
until 9 hours. And the transfection of Piwil2-siRNA led to opposite
effects in a parallel time-course profile. (Fig. 2C) These results
demonstrated that phosphorylation of STAT3 protein occurred
earlier than P53 regulation and suggested STAT3 activity may
play as an upstream factor of P53 in Piwil2-induced anti-apoptosis.
Figure 1. Piwil2 represses P53 and inhibits apoptosis. A, P53 expression was significantly repressed by Piwil2. HeLa cells were transfected with
same amount of empty plasmid (+pcDNA3.1), pcDNA3.1-Piwil2 (+Piwil2) or Piwil2-specific siRNA (+siRNA), harvested and examined by western blot
analysis (upper) and real-time qPCR (lower). Anti-GAPDH antibody and primers were applied as internal control, respectively. B, Western blot analysis
of expression of HSP90, STAT3, P21 and MDM2 in HeLa cells, suggesting that P21 was downregulated by Piwil2. C, Apoptosis analysis of transfected
HeLa cells with Annexin V/PI double staining detected by a flow cytometer. Western blot analysis of p53 expression was also performed, suggesting
that Stat3 knockdown can rescue the expression of p53 inhibited by overexpressed Piwil2. D, Immunoprecipitation analysis showed that STAT3,
rather than P53 or HSP90, can directly associated with Piwil2.
doi:10.1371/journal.pone.0030999.g001
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another tumor cell line HepG2, revealing that Piwil2 functioned
similarly in HepG2 in contrast to HeLa cells (Fig. 2D).
To verify this hypothesis, we determined the interaction
between STAT3 protein and P53 promoter using chromatin
immunoprecipitation (ChIP) assay followed by Real-time quanti-
tative PCR. Bioinformatic examination revealed that a potential
STAT binding site which contains a consensus sequence
TT(N4)AA or TT(N5)AA [19,23] can be located 179 bp upstream
of the noncoding first exon of human P53 (NM_000546.4)
(Fig. 3A).
In additional, overexpression of Piwil2 led to an increased level
of interaction between STAT3 and P53 promoter 12 hours after
transfection. In contrast, knockdown of Piwil2 suppressed such
interaction (Fig. 3B). To investgate whether P53 was silenced at
transcription level, methylation state of H3K4 and H3K9 in P53
promoter region were analyzed by ChIP method. The results
showed that transient transfection of Piwil2 resulted in approxi-
mately a 2-folder increase in the methylation state of H3K9 and
significant decrease in the methylation state of H3K4, both of
which represented the transcriptional silencing of P53. In contrast,
knockdown of Piwil2 resulted in significant decrease in the
methylation state of H3K9 and increase in the methylation of
H3K4 (Fig. 3C).
In order to identify the specific sequence bound by STAT3, the
indicated region of p53 gene promoter was mutated and
constructed into a pVAX-Luciferase plasmid. Dual-luciferase
analysis showed that the translation of mRNAs containing the
wildtype but not mutated STAT3 binding site was downregulated
by Piwil2 (Fig. 3D).
Src Kinase is required for STAT3 phosphorylation by
Piwil2
To search for potential upstream factors of STAT3, HeLa cells
were treated with tyrosine kinase inhibitors before transfection.
Western analysis showed that overexpression of Piwil2 still
enhanced STAT3 phosphorylation in HeLa cells pretreated with
JAK inhibitor AG490. Thus we can rule out JAK family kinases as
a phosphate giver. However, in HeLa cells pretreated with Src
inhibitor PP2, STAT3 phosphorylation was blocked after
overexpression of Piwil2 (Fig. 4A). This result indicated that Src,
rather than JAK, played a role in Piwil2-induced STAT3
phosphorylation, which was further confirmed by western blotting
using phosphorylated c-Src antibody. Analysis revealed that Y416-
Figure 2. Piwil2 induces phosporylation of STAT3. A, Western blot analysis showed that phosphorylation level of STAT3 was significantly
increased 12 hours after being transient transfected with Piwil2. However, at 24 hours after transfection, STAT3 phosphorylation level had almost
returned to normal. Similar while opposite profile was observed followed transfection of Piwil2-siRNA. Nevertheless, stable transfectants of Piwil2 (ST)
showed constantly high STAT3 activity. B, pYSTAT3 was subcellular localized in Piwil2 transfected cells by using immunofluorescence. Signal of FITC-
labeled secondary antibody was observed significantly increased in cytoplasm 6 hours after transfection, and expanded to nucleus 12 hour after
transfection. C, time-course analysis showed that STAT3 phosphorylation was notably sensitive to changes in Piwil2 level and responded rapidly, at
least 6 hours before P53 regulation. D, Western blot analysis revealed that Piwil2 induced STAT3 phosphorylation and repressed P53 in HepG2 cells.
doi:10.1371/journal.pone.0030999.g002
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first exon of P53. B&C, ChIP assays of chromatin prepared from transfected HeLa cells using the indicated antibodies followed by real-time PCR,
which amplified a 127-bp region spanning the Stat3-binding site described above. B, STAT3 binding activity to P53 promoter showed significant
changes 12 hours after transfection of pcDNA3.1-Piwil2 or siRNA. C, histone methylation level of P53 promoter was examined with anti-di-
methylation H3K4 (darker) and anti-di-methylation H3K9 (lighter) antibody, respectively. D, Piwil2 suppressed the translation of P53 by regulating its
promoter. HeLa cells were transfected with the indicated constructs. Relative luciferase activity is the ratio between firefly luciferase and renilla
luciferase, adjusted to 100%.
doi:10.1371/journal.pone.0030999.g003
Figure 4. c-Src involved in Piwil2-induced STAT3 phosphorylation. HeLa cells pretreated with JAK-inhibitor AG490 or Src-inhibitor PP2 were
transfected with same amount of empty plasmid (+pcDNA3.1), pcDNA3.1-Piwil2 (+Piwil2) or Piwil2-specific siRNA (+siRNA), harvested and examined
by western blot analysis. Non-pretreated cells were employed as negative control (NC). The results showed that PP2 rather than AG490 can deplete
the activity of c-Src and block the regulation to STAT3 phosphorylation and P53 expression by Piwil2.
doi:10.1371/journal.pone.0030999.g004
Piwil2 Activates STAT3 and Inhibits P53
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Piwil2 transfection, while the level of pY416 c-Src decreased after
Piwil2-siRNA transfection (Fig. 4B).
A triple protein-protein complex is formed when Piwil2
recruits STAT3 to c-Src
The effect of Piwil2 on STAT3 phosphorylation was investi-
gated by co-immunoprecipitation (coIP) assay, revealing that the
,110 kD Piwil2 protein was physically associated with STAT3
and c-Src, while STAT3 was also observed associating with c-Src
(Fig. 5A). Meanwhile, the absence of STAT3 blocked the binding
between Piwil2 and c-Src (Fig. 5B), whereas Piwil2 knockdown led
to decreased c-Src signal detected in STAT3 immunoprecipitates
(Fig. 5C). The results suggested that Piwil2 played an essential role
in the assocaiation between STAT3 and non-receptor tyrosine
kinase c-Src. Thus they formed a triple protein-protein complex
and STAT3 was phosphorylated and activated.
To further investigate the interaction between Piwil2, STAT3
and c-Src, we constructed a series of Piwil2 deletion mutants to
identify the functional domains required for phosphorylating
STAT3. Two Piwil2 mutants, one harbored a deletion of PAZ
conserved domain while the other lacks both PAZ and PIWI
domains, failed to bind with STAT3, while other mutants retained
the ability (Fig. 6A and B). Notably, the PAZ-deleted mutants
failed to induce STAT3 phosphorylation (Fig. 6C) and inhibit cell
apoptosis (Fig. 6D), confirming the potential role of PAZ domain
of Piwil2.
Discussion
IthasbeenreportedthatPiwil2transcriptswerewidelydetectedin
various tumors or cancer cell lines, and played important roles in
tumorigenesis and apoptosis inhibition [13,24–26]. However, the
mechanism underlying piwil2-mediated tumor development re-
mained unclear yet. To investigate the signaling pathway through
which Piwil2 suppresses the apoptosis of cancer cells, we studied the
relationship between Piwil2 and its potential target genes. Our
research demonstrated that Piwil2 can efficiently activate STAT3 by
phosphorylating STAT3 at residue Tyr705 (Fig. 2), which leads to
dimerization ofSTAT3and downstream targetscontrol [18,20]. We
next examined whether Piwil2 also enhanced STAT3 DNA binding
activity. Our results indicated that induced byPiwil2 overexpression,
STAT3 DNA binding activity to P53 promoter was significantly
increased, leading to epigenetic modification and silencing of P53
gene(Fig. 3B and C).Thisfoundingwas supported bypreviousstudy
on roles of STAT3 in regulating P53 by Niu et al [19].
Activation of STAT3 required tyrosine kinases activity, which
Piwi family proteins have not yet been reported to possess. JAK/
STAT3 pathway is well-known to respond extracellular signal and
regulate expression of various genes [27–29]. However, AG490, a
specific JAK/STAT3 pathway inhibitor, showed little effort in
blocking Piwil2-induced STAT3 phosphorylation (Fig. 4A), sug-
gesting that JAK family kinases may not be involved in Piwil2-
STAT3-P53 pathway. So we next analyzed another candidate Src,
a family of non-receptor tyrosine kinases that has been reported to
constitutively activate STAT3 during oncogenic transformation
[30–33]. Western blot experiments revealed that the overexpres-
sion of Piwil2 in PP2-treated HeLa cells failed to increase
pYSTAT3 level, while the knockdown of Piwil2 made no
significant decrease of pYSTAT3 compared to the control.
Further experiments revealed that overexpressed Piwil2 can
increase the phosphorylation level on Tyr416 of c-Src, which
indicates tyrosine kinase activity of the protein (Fig. 4B).
Immunoprecipitation assay demonstrated that Piwil2, STAT3
and c-Src can physically associated with each other. However,
silencing of Piwil2 or STAT3 may lead to significantly repressed
binding level between c-Src and the other protein(Fig. 5),
suggesting that Piwil2 played an essential role in the association
between STAT3 and non-receptor tyrosine kinase c-Src. Thus
they formed a triple protein-protein complex and STAT3 was
phosphorylated and activated.
Based on our results and previous finding about STAT and P53,
we demonstrated that Piwil2 inhibits P53 involved apoptosis
through Src-STAT3 pathway in HeLa cells (Fig. 7). Our
immunoprecipitation analysis shows that Piwil2 can directly
associate with STAT3 via its PAZ domain and form a Piwil2/
STAT3/c-Src triple protein-protein complex. As shown in Figure 1
and Figure 2, our present study shows that the activation of STAT3
phosphorylated by c-Src at residue Tyr705 is significantly increased
in Piwil2 overexpressed HeLa cells. The phosphorylated STAT3
proteins dimerize and translocate to nucleus as reviewed by Burdon
et al [22]. Furthermore, dimerized STAT3 proteins bind to the
promoter region of P53 gene and repress P53 expression.
To study the function of human Piwil2 gene, alias HILI in Hela
cells, we analyzed its relationship with P53 and apoptosis. As
variant deletions or mutations of P53 have been observed in a
great number of tumors, the underlying mechanism of anti-
apoptosis may differ among variant cancer cells. However, our
results demonstrated that Piwil2 functioned to induce STAT3
phosphorylation and prevent expression of P53 at least in two cell
lines (HeLa and HepG2). These investigations will provide a novel
insight into roles of Piwil2 in tumor cells.
Figure 5. Interaction between Piwil2, c-Src and STAT3. A, cell
lysates were prepared and subjected to coIP assays. TP, total protein
lysates as positive control; NC, protein A+G agarose incubated with
total protein lysate to detect nonspecific interaction (negative control,
detected with corresponding antibodies). B, In STAT3-silenced cells
(STAT32, transfected with STAT3-specific siRNA), the binding between
Piwil2 and c-Src was repressed in contrast to lysates of control cells
(STAT3+, transfected with nonspecific siRNA). C, the binding between c-
Src and STAT3 was repressed in Piwil2-silenced cells (Piwil2-, transfected
with Piwil2-specific siRNA).
doi:10.1371/journal.pone.0030999.g005
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Plasmids and siRNAs
The coding sequences of Piwil2, STAT3 and c-Src were
amplified by RT-PCR and cloned into the vector pcDNA3.1
(Invitrogen, USA) with an upstreaming Myc- or HA-tag
respectively. TRIpure reagent, a gel extraction kit, and a high
purity plasmid preparation kit were purchased from Bioteke
Corporation (Beijing, China) for total RNA extraction, PCR
product purification, and plasmid preparation. The specific
siRNAs (described in Table 1) and universal negative control
dicer substrate duplex were synthesized and purchased from
RiboBio Co. Ltd (Guangzhou, China).
The putative STAT3 binding site in p53 gene promoter was
obtained and mutated through a PCR method, then cloned into a
pVAX-Luciferase plasmid (maintained in our laboratory). The
sequences of the PCRprimers used are as follows: wildtype forward:
59- CGC GGA TCC AGC TCT GGC TTG CAG AAT TTT
CCA C -39; mutated forward: 59- CGC GGA TCC AGC TCT
GGC GGG CAG AAT TTT CCA C -39; universal reverse: 59-
CCG GAA TTC CCG GAG GAA GCA AAG GAA ATG G -39.
Cell culture
Cervical cancer cell line HeLa was maintained in our laboratory
[34]; hepatocellular carcinoma cell line HepG2 was obtained from
State Key Laboratory of Biotherapy and Cancer Centre of West
China Hospital [35]. Both cell lines were maintained in RPMI-
1640 medium (Gibco, USA) containing 10% heat-inactivated
FBS, 100 U/ml penicillin and 100 mg/ml streptomycin, on
25 cm
2 culture dishes in a humidified atmosphere containing
5% CO2 incubator at 37uC. The cells were passaged by
trypsinization every 2–3 days. The transfection was performed
with lipofectamine 2000 solution (Invitrogen, USA) according to
the manufacturer’s protocol and transfected cells were harvested
and analyzed 24 hours after transfection, unless stated otherwise.
Empty plasmid DNA was applied to transfection as negative
control. And in some experiments, stable overexpression transfec-
tants selected by being cultured in medium containing 1 mg/ml of
G418 (Solarbio, China) for one month were also examined. To
inhibit tyrosine kinase activity, HeLa cells were pretreated with
25 mM AG490 (Sigma-Aldrich, USA) for 24 hours or 10 mM PP2
(Sigma-Aldrich, USA) for 30 minutes. All following experiments
were repeated at least three times unless stated otherwise.
Apoptosis assay
Apoptotic rates were analyzed by a COULTER EPICS XL
flow cytometer (Beckman, USA) using an Annexin V-EGFP
Apoptosis Detection Kit (Bestbio, Shanghai). Annexin V/PI
staining and fluorescence intensity measurements were performed
according to the manufacturer’s instruction.
Figure 6. The specificity and domains of Piwil2-Stat3 interaction. A, schematic of different Piwil2 deletion constructs. B, Piwil2 deletion
mutants with HA-tag were respectively co-transfected in HeLa cells with Myc-tagged STAT3, coIP assay revealed that mutants with PAZ domain
deletion (pPAZ and pP+P) failed to bind with STAT3. C, Western blot analysis showed that PAZ deletion mutants failed to induce phosphorylation of
STAT3. D, Apoptosis analysis showed that PAZ deletion mutants failed to inhibit apoptosis in transfected HeLa cells.
doi:10.1371/journal.pone.0030999.g006
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Harvested cells were lysed in ice-cold universal protein
extraction buffer (Bioteke, Beijing) supplemented with protease
inhibitor cocktail (Roche, USA) for 30 min. Cell lysates were
separated on 4–12% SDS-page gel and transferred to a
nitrocellulose membrane. Membranes were blocked in TBS-T
Buffer (50 mM Tris-HCl, 150 mM NaCl, 0.1% Tween, PH 7.6)
supplemented with 5% nonfat dry milk. The membranes were
incubated overnight at 4uC with the indicated primary antibody:
rabbit polyclonal anti-Piwil2 (Santa Cruz, USA), rabbit polyclonal
anti-STAT3 (Abcam, UK), rabbit polyclone anti-pYSTAT3
(CST, USA), rabbit polyclonal anti-c-Src (Abcam, UK), rabbit
polyclonal anti-pY416-c-Src (CST, USA), mouse monoclonal anti-
GAPDH (Boster, China), mouse monoclonal anti-HA-tag (CST,
USA), and rabbit polyclonal anti-Myc-tag (Santa Cruz, USA),
followed by 5 minutes washes in TBS-T for three times and
incubation with HRP-labeled secondary antibody (Zhongshan
Goldenbridge, China) in TBS-T for 1 hour at RT. The
membranes were detected with chemiluminescent HRP substrate
(Millipore, USA).
Immunofluorescence
Transfected cells were fixed with 4% formaldehyde in PBS for
15 min, permeabilized with 0.5% Triton X-100 for 10 min,
blocked with 1% BSA for 30 min, incubated overnight at 4uC with
primary antibody and finally incubated with FITC-labeled
secondary antibody (Zhongshan Goldenbridge, China) for 1 hour
at RT. Each step was followed with 5 minutes washes in PBS
twice. The prepared specimens were counterstained with 5 mg/
mlDAPI for 2 min and observed with a fluoresence microscope
(Olympus, Japan).
Immunoprecipitation
Prepared cell lysates were incubated with 0.8 mg antibody
against HA-tag or Myc-tag for 2 hours at 4uC with gentle
inverting, then incubated with 20 ml of protein G&A agarose
(Beyotime, China) overnight, and precipitated by centrifugation at
12,000 g for 1 min. Complexes were washed four times in ice-cold
PBS Buffer (pH 7.4), and electrophoresed on 4–12% SDS-page
gel. Western blot detection was carried out as described earlier.
Chromatin immunoprecipitation (ChIP) assays and real-
time PCR
Preparation of chromatin-DNA and ChIP assays were per-
formed as described by the manufacturer’s protocol of EZ-Zyme
Chromatin Prep Kit (Millipore, USA) and Chromatin Immuno-
precipitation Kit (Millipore, USA). Antibody against di-methylated
H3K4 and di-methylated H3K9 were purchase from Abcam
(UK). Purified DNA was subjected to PCR using primers specific
for a 127-bp region spanning the STAT3-binding site in the P53
promoter. The sequences of the PCR primers used are as follows:
Table 1. Sequences of deployed siRNAs.
siRNAs Sequences
Piwil2 sense CUA UGA GAU UCC UCA ACU ACA GAA G [24]
Piwil2 antisense CUU CUG UAG UUG AGG AAU CUC AUA GUU [24]
c-Src sense AAC AAG AGC AAG CCC AAG GAU dTdT
c-Src antisense AUC CUU GGG CUU GCU CUU GUU dTdT
STAT3 sense CAU CUG CCU AGA UCG GCU AdTdT
STAT3 antisense UAG CCG AUC UAG GCA GAU GdTdT
P53 sense GAC UCC AGU GGU AAU CUA CdTdT
P53 antisense GUA GAU UAC CAC UGG AGU CdTdT
Nonspecific duplex siR-Ribo
TM Negative Control (Ribobio, China)
doi:10.1371/journal.pone.0030999.t001
Figure 7. A schematic model for the involvement of Piwil2 in anti-apoptosis in HeLa cells. 1, Piwil2 binds with monomeric STAT3 and
recruited it to c-Src. 2, STAT3 is phosphorylated by c-Src and then dimerized. 3, dimeric pYSTAT3 translocates into the nucleus and bind to P53
promoter, repress P53 transcription and thus inhibit apoptosis.
doi:10.1371/journal.pone.0030999.g007
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P53 reverse: 59-CCG GAG GAA GCA AAG GAA ATG G-39;
P53 TaqMan: 59-FAM-CCG CAG TTT CTT CCC ATG CAC
CTG-TAMRA-39. Quantitative PCRs were performed in an
iCycler IQ real-time PCR Detection System (BioRad, USA), with
a first denaturation step at 94uC for 10 min, followed by 45 cycles
comprising denaturation at 94uC for 20 s, annealing at 58uC for
30 s and extension at 72uC for 40 s. Inputs removed before
applying antibody were deployed to normalize for differences in
the amount of DNA in each PCR.
Dual-Luciferase Assay
For luciferase analysis, 100 ng plasmid DNA and 100 ng renilla
control plasmid were transfected into HeLa cells. Dual luciferase-
activity assays were performed 48 hours after transfection
according to the manufacturer’s directions (Promega). Three
independent experiments were set up in every term.
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